Neogenix Oncology, Inc. (Neogenix) announced today that researchers at Duke University Medical Center have received approval to move forward with a Phase I trial of the company's lead therapeutic antibody, NPC-1C, in patients with advanced stage pancreatic or colorectal cancer. Duke joins Johns Hopkins Hospital which is already conducting the Phase I trial of NPC-1C. In addition to Johns Hopkins, North Shore - LIJ has also enrolled patients on this multi-center study.
“I am pleased to be participating in the clinical evaluation of this agent in a study population with limited treatment options”
NPC-1C is a novel, chimeric monoclonal antibody intended for the treatment of advanced pancreatic and colorectal cancer, and is the first of the Neogenix pipeline of antibodies that target specific cancers. Pre-clinical studies have demonstrated that NPC-1C specifically targets pancreatic and colorectal cancer sparing healthy tissue.
"We are pleased to partner with the investigators at Duke University Medical Center as they join Johns Hopkins on this study. We look forward to fostering the relationships with both of these prestigious medical establishments for future Neogenix therapeutic development. There is a serious need for new therapies for life-threatening cancers, especially pancreatic cancer where very few treatment options exist. Having a treatment that would target the cancer specifically and spare healthy organs would represent a significant advancement in the treatment of this disease", said Neogenix Chief Executive Officer, Philip M. Arlen, MD.
"I am pleased to be participating in the clinical evaluation of this agent in a study population with limited treatment options," said Michael A. Morse, M.D., associate professor of medicine at Duke University Medical Center, Principal Investigator on the study.
MONET: New AI tool enhances medical imaging with deep learning and text analysis